DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intermittent Preventive Treatment in Infant in Mali

Information source: University of Bamako
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria

Intervention: Sulfadoxine pyrimethamine (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Bamako

Official(s) and/or principal investigator(s):
Alassane Dicko, MD, Principal Investigator, Affiliation: Faculty of Medicine, Pharmacy and Dentistry; University of Bamako
Ogobara K Doumbo, MD, Study Director, Affiliation: Faculty of Medicine, Pharmacy and Dentistry; University of Bamako

Summary

Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines. Thus IPTi was seen as a potential public health tool of great benefit to the children of Africa and a logical addition to the Immunization Plus package. The objectives of this operational researcher were

- to develop an implementation model for IPTi in the health care system in Mali

- to assess its impact on the EPI vaccines and other health interventions coverage

- and on molecular makers of resistance to SP

Clinical Details

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Primary outcome:

EPI vaccines and other health interventions coverage

Molecular makers of resistance of P. falciparum to Sulfaxodine- pyrimethamine

Detailed description: The study was implemented in districts of the region of Koulikoro; the district of Koulikoro and the district of Kolokani. The whole district of Koulikoro was covered by the intervention while in Kolokani, the 22 health areas (sub districts) were randomized in 1: 1 ratio with the intervention in 11 health areas and the other 11 serving as control for the assessment of the impact of IPTi implementation on EPI vaccines and other health interventions coverage as well as its impact on the resistance to SP. The implementation

consisted of administration of ½ tablet of Sulfadoxine - Pyrimethamine with EPI vaccines

(DTP2, DTP3 and Measles vaccine) from December 2006 to December 2007.

Eligibility

Minimum age: N/A. Maximum age: 23 Months. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Resident of Kolokani, Mali

- Age less than 24 months

Exclusion Criteria:

- Not Resident of Kolokani

- Age of 24 months or above

Locations and Contacts

Malaria Research & Training Center; Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako 0000, Mali
Additional Information

Starting date: October 2006
Last updated: October 3, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017